Avastin After Recurrence in Glioblastoma Shows No Benefit

 

Continuing Avastin (bevacizumab) in patients with recurrent glioblastoma after progression of the disease does not improve patient outcomes, according to results from the phase 2 CABARET trial.

• Tweet
• Share
• Share
• Share
• Share

Sign up here with your email